Boston Scientific Corp
BSX105.410USD
+0.490+0.47%
Handelsschluss 08/01, 16:00（ET）Kurse um 15 Minuten verzögert
155.92BMarktkapitalisierung
76.73KGV TTM
mehr Informationen über Boston Scientific Corp Unternehmen
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Unternehmensinformationen
BörsenkürzelBSX
Name des UnternehmensBoston Scientific Corp
IPO-datumMay 19, 1992
Gegründet am1979
CEOMr. Michael F. (Mike) Mahoney
Anzahl der mitarbeiter53000
WertpapierartOrdinary Share
GeschäftsjahresendeMay 19
Addresse300 Boston Scientific Way
StadtMARLBOROUGH
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl01752-1234
Telefon15086834000
Websitehttps://www.bostonscientific.com/en-US/Home.html
BörsenkürzelBSX
IPO-datumMay 19, 1992
Gegründet am1979
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.98K
+5.88%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
37.02K
+5.96%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
5.63K
+58.67%
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.08K
-58.23%
Mr. Arthur Crosswell Butcher
Mr. Arthur Crosswell Butcher
Executive Vice President, Group President, MedSurg and Asia Pacific
Executive Vice President, Group President, MedSurg and Asia Pacific
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
Ms. Meghan Scanlon
Ms. Meghan Scanlon
Senior Vice President and President - Urology
Senior Vice President and President - Urology
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.98K
+5.88%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
37.02K
+5.96%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
5.63K
+58.67%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Electrophysiology
730.00M
15.66%
Interventional Cardiology Therapies
697.00M
14.95%
Endoscopy
673.00M
14.43%
Peripheral Interventions
656.00M
14.07%
Urology
633.00M
13.57%
Other
1.27B
27.32%
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.96B
63.48%
EMEA (Europe, Middle East and Africa)
846.00M
18.14%
Asia Pacific
701.00M
15.03%
Latin America and Canada
155.00M
3.32%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Electrophysiology
730.00M
15.66%
Interventional Cardiology Therapies
697.00M
14.95%
Endoscopy
673.00M
14.43%
Peripheral Interventions
656.00M
14.07%
Urology
633.00M
13.57%
Other
1.27B
27.32%
Aktionärsstatistik
Aktualisiert: Thu, Jul 24
Aktualisiert: Thu, Jul 24
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.05%
Fidelity Management & Research Company LLC
7.94%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Global Advisors (US)
4.36%
PRIMECAP Management Company
2.47%
Other
70.92%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.05%
Fidelity Management & Research Company LLC
7.94%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Global Advisors (US)
4.36%
PRIMECAP Management Company
2.47%
Other
70.92%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
52.58%
Investment Advisor/Hedge Fund
28.08%
Hedge Fund
3.98%
Pension Fund
2.91%
Research Firm
2.45%
Bank and Trust
1.71%
Sovereign Wealth Fund
1.54%
Private Equity
0.20%
Insurance Company
0.19%
Other
6.37%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
2738
1.39B
93.92%
-1.01M
2025Q1
2744
1.39B
93.81%
-5.31M
2024Q4
2559
1.38B
93.61%
+1.09M
2024Q3
2417
1.37B
92.76%
-24.32M
2024Q2
2341
1.37B
93.29%
-18.17M
2024Q1
2227
1.37B
93.23%
-40.14M
2023Q4
2171
1.39B
94.95%
-25.34M
2023Q3
2110
1.39B
95.17%
-6.29M
2023Q2
2081
1.38B
95.67%
-15.63M
2023Q1
2012
1.36B
94.85%
-23.81M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
133.95M
9.05%
+1.70M
+1.28%
Mar 31, 2025
Fidelity Management & Research Company LLC
117.45M
7.94%
-3.75M
-3.09%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
77.81M
5.26%
+1.08M
+1.41%
Mar 31, 2025
State Street Global Advisors (US)
64.48M
4.36%
+514.79K
+0.80%
Mar 31, 2025
PRIMECAP Management Company
36.50M
2.47%
-432.72K
-1.17%
Mar 31, 2025
Wellington Management Company, LLP
33.20M
2.24%
-2.97M
-8.21%
Mar 31, 2025
Geode Capital Management, L.L.C.
31.80M
2.15%
+1.18M
+3.84%
Mar 31, 2025
Capital World Investors
28.56M
1.93%
+658.82K
+2.36%
Mar 31, 2025
Managed Account Advisors LLC
21.29M
1.44%
+3.60M
+20.36%
Mar 31, 2025
The Bollard Group, LLC
20.49M
1.39%
-242.40K
-1.17%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 6 hours ago
Aktualisiert: 6 hours ago
Name
Anteil
iShares U.S. Medical Devices ETF
11.22%
Goldman Sachs Future Health Care Equity ETF
8.79%
Invesco Dorsey Wright Healthcare Momentum ETF
5.45%
NYLI Healthy Hearts ETF
5.03%
JPMorgan Healthcare Leaders ETF
4.31%
Tema Heart & Health ETF
3.68%
iShares Health Innovation Active ETF
3.61%
Health Care Select Sector SPDR Fund
3.25%
Proshares Ultra Health Care
3.25%
Knowledge Leaders Developed World ETF
3.23%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil11.22%
Goldman Sachs Future Health Care Equity ETF
Anteil8.79%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil5.45%
NYLI Healthy Hearts ETF
Anteil5.03%
JPMorgan Healthcare Leaders ETF
Anteil4.31%
Tema Heart & Health ETF
Anteil3.68%
iShares Health Innovation Active ETF
Anteil3.61%
Health Care Select Sector SPDR Fund
Anteil3.25%
Proshares Ultra Health Care
Anteil3.25%
Knowledge Leaders Developed World ETF
Anteil3.23%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
